Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 25.37 USD 2.8% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

APLS Price Targets Summary
Apellis Pharmaceuticals Inc

Wall Street analysts forecast APLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APLS is 36.24 USD with a low forecast of 19.19 USD and a high forecast of 57.75 USD.

Lowest
Price Target
19.19 USD
24% Downside
Average
Price Target
36.24 USD
43% Upside
Highest
Price Target
57.75 USD
128% Upside
Apellis Pharmaceuticals Inc Competitors:
Price Targets
KURA
Kura Oncology Inc
213% Upside
005690
Pharmicell Co Ltd
2% Upside
CUV
Clinuvel Pharmaceuticals Ltd
106% Upside
002007
Hualan Biological Engineering Inc
27% Upside
688278
Xiamen Amoytop Biotech Co Ltd
20% Upside
ARGX
argenx SE
11% Upside
6855
Ascentage Pharma Group International
80% Upside
IPH
Innate Pharma SA
204% Upside

Revenue
Forecast

Revenue Estimate
Apellis Pharmaceuticals Inc

The compound annual growth rate of Apellis Pharmaceuticals Inc's revenue for the next 3 years is 11%.

N/A
Past Growth
11%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Apellis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Apellis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is APLS's stock price target?
Price Target
36.24 USD

According to Wall Street analysts, the average 1-year price target for APLS is 36.24 USD with a low forecast of 19.19 USD and a high forecast of 57.75 USD.

What is Apellis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
11%

The compound annual growth rate of Apellis Pharmaceuticals Inc's revenue for the next 3 years is 11%.

Back to Top